Clinical benefits of direct-acting antivirals therapy in hepatitis C virus patients with hepatocellular carcinoma: A systematic review and meta-analysis.

Hui LiuXiao-Li YangZhao-Ru DongZhi-Qiang ChenJian-Guo HongDong-Xu WangTao Li

Published in: Journal of gastroenterology and hepatology (2022)

DAAs therapy can prevent recurrence and improve OS of HCV-related HCC patients, especially for patients with SVR. Further prospective randomized controlled trial is warranted to validate these results.

Keyphrases

hepatitis c virus
randomized controlled trial
end stage renal disease
human immunodeficiency virus
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
study protocol
peritoneal dialysis
stem cells
bone marrow
cell therapy